VEGFA and diabetes mellitus: Ranibizumab has numerous advantages such as strong specificity, high bioavailability, and strong permeability, and can effectively inhibit VEGF in the retina, prevent vascular leakage, and reduce retinal edema.10 Antoszyk et al.15 used ranibizumab in patients with diabetes retinopathy with or without diabetes ME, and confirmed that it can improve patients’ vision and alleviate clinical symptoms.